Ryvu Therapeutics SA Total Liabilities
Ryvu Therapeutics SA total liabilities. Based on the latest financial reports, Ryvu Therapeutics SA (RVU) has total liabilities worth zł159.63 Million PLN (≈ $43.93 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check RVU financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ryvu Therapeutics SA (2010–2025)
Total liabilities of Ryvu Therapeutics SA from 2010 to 2025. This chart illustrates how Ryvu Therapeutics SA's total liabilities have evolved over time, based on quarterly financial data. Explore RVU strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Ryvu Therapeutics SA Competitors by Total Liabilities
The table below lists competitors of Ryvu Therapeutics SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Taegu Broadcasting Corporation
KQ:033830
|
Korea | ₩6.35 Billion |
|
CVC Income & Growth Limited
LSE:CVCE
|
UK | €355.00K |
|
Schloss Wachenheim AG
F:SWA
|
Germany | €260.86 Million |
|
Minerva Neurosciences Inc
NASDAQ:NERV
|
USA | $348.04 Million |
|
Thuan Duc JSC
VN:TDP
|
Vietnam | ₫3.36 Trillion |
|
AS HARJU ELEKTER EO 063
F:HD8
|
Germany | €60.34 Million |
|
Excel Cell Electronic Co Ltd
TW:2483
|
Taiwan | NT$1.72 Billion |
|
Asefa Public Company Limited
BK:ASEFA
|
Thailand | ฿2.43 Billion |
Liability Composition Analysis (2010–2025)
This chart breaks down Ryvu Therapeutics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see RVU total assets.
Liquidity & Leverage Metrics
Ryvu Therapeutics SA Total Liabilities Ratios Explained
Ryvu Therapeutics SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ryvu Therapeutics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ryvu Therapeutics SA (2010–2025)
The table below shows the annual total liabilities of Ryvu Therapeutics SA from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | zł153.69 Million ≈ $42.30 Million |
-34.57% |
| 2024-12-31 | zł234.89 Million ≈ $64.65 Million |
+63.56% |
| 2023-12-31 | zł143.61 Million ≈ $39.52 Million |
+9.14% |
| 2022-12-31 | zł131.59 Million ≈ $36.21 Million |
+121.55% |
| 2021-12-31 | zł59.39 Million ≈ $16.35 Million |
-17.42% |
| 2020-12-31 | zł71.92 Million ≈ $19.79 Million |
+13.92% |
| 2019-12-31 | zł63.13 Million ≈ $17.38 Million |
+3.77% |
| 2018-12-31 | zł60.84 Million ≈ $16.74 Million |
+53.72% |
| 2017-12-31 | zł39.58 Million ≈ $10.89 Million |
+18.46% |
| 2016-12-31 | zł33.41 Million ≈ $9.19 Million |
+81.95% |
| 2015-12-31 | zł18.36 Million ≈ $5.05 Million |
+4.63% |
| 2014-12-31 | zł17.55 Million ≈ $4.83 Million |
+18.19% |
| 2013-12-31 | zł14.85 Million ≈ $4.09 Million |
+51.28% |
| 2012-12-31 | zł9.82 Million ≈ $2.70 Million |
+62.45% |
| 2011-12-31 | zł6.04 Million ≈ $1.66 Million |
-31.08% |
| 2010-12-31 | zł8.77 Million ≈ $2.41 Million |
-- |
About Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myel… Read more